DelveInsight

View All

Delveinsight
Head and Neck Squamous Cell Carcinoma -Pipeline Insights, 2016

DelveInsight, the leading market research and consulting company has added new report  Head and Neck Squamous Cell Carcinoma -Pipeline Insights, 2016 to its portfolio. With this launch Delveinsight now has 700+ Reports on Indication Pipeline Insight. In addition to this our research expertise provides our clien...

Find More

Delveinsight
  Pancreatic Cancer-Pipeline Insights, 2016

DelveInsight, the leading market research and consulting company has added new report   Pancreatic Cancer-Pipeline Insights, 2016 to its portfolio. With this launch Delveinsight now has 700+ Reports on Indication Pipeline Insight. In addition to this our research expertise provides our clients with up to date i...

Find More

Delveinsight
Peripheral Lung Cancer Pipeline Insights, 2016

DelveInsight, the leading market research and consulting company has added new report Peripheral Lung Cancer-Pipeline Insights, 2016 to its portfolio. With this launch Delveinsight now has 700+ Reports on Indication Pipeline Insight. In addition to this our research expertise provides our clients with up to date inf...

Find More

Delveinsight
DelveInsight’s Market Research Reports

DelveInsight has established its strong presence in therapeutic areas and has launched Analytical Reports on indication, mechanism of actions, drugs, Global API Manufacturers and specialized Reports on Gene Therapy, Anticoagulants, PD-1 and PDL-1, CART and Antibody Drug conjugates. After tremendous success last yea...

Find More

Rising of Orphan Drug Development

Introduction: Any disease that affects less than 200,000 patients or 1 in 1500 is termed as a rare disease. There are around 5000 to 8000 rare disease reported, out which only 10% have cure. According to the European Organization for rare disease, 80% of rare diseases are genetic in nature. Some of the rare disease...

Find More

Delveinsight
Orphan drug development strategies

Introduction A disease that has not been adopted by the pharmaceutical industry because it provides little financial incentive for the private sector to make and market new medications to treat or prevent it.  An orphan disease may be a rare disease or a common disease that has been ignored because it is far more pr...

Find More

Delveinsight
“Endometrial Cancer – Pipeline Insights, 2015”- A DelveInsight’s Report

DelveInsight, the leading market research and consulting company has added a new report “Endometrial Cancer - Pipeline Insights, 2015” to its portfolio. With this launch DelveInsight now has 700+ Reports on Indication Pipeline Insight. In addition to this, our research expertise provides our clients with up to date ...

Find More

Delveinsight
PD-1 and PD-L1 inhibitors – Competitive Landscape, Pipeline and Market Analysis, 2015 – A DelveInsight Report

DelveInsight has made strong presence in Oncology market with 100+ Reports on Oncology based Indications & Mechanism of Action (MOA).DelveInsight Report, PD-1 and PD-L 1 inhibitors – Competitive Landscape, Pipeline and Market Analysis, 2015 has received great response and feedback from client...

Find More

Delveinsight
Systemic Juvenile Idiopathic Arthritis -Pipeline Insights, 2015

Juvenile idiopathic arthritis (JIA) Juvenile idiopathic arthritis (JIA) affects children who are less than 16 years old, commonly occurs in children from the ages of 7 to 12. The disease may occur in adolescents as old as 15 years of age, as well as in infants. Between 10% and 15% of all children with JIA have SJIA....

Find More

Delveinsight
Bile Duct Cancer (Cholangiocarcinoma) -Pipeline Insights, 2015

DelveInsight, the leading market research and consulting company has added new report  Bile Duct Cancer (Cholangiocarcinoma) -Pipeline Insights, 2015 to its portfolio. With this launch DelveInsight now has 700+ Reports on Indication Pipeline Insight. In addition to this, our research expertise provides our clients w...

Find More